Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of vosaroxin when given
together with azacitidine in treating patients with myelodysplastic syndromes. Drugs used in
chemotherapy, such as vosaroxin and azacitidine, work in different ways to stop the growth of
cancer cells, either by killing the cells or by stopping them from dividing.